Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q1 2023
Net profit, assets, equity and cash flow for Q1 2023, against the same period a year earlier, from the published financial statements.
Net profit9.44 millionEGP · −69.2% vs the same period a year earlier
Total assets798 millionEGP · +24.5% vs the same period a year earlier
Shareholders' equity376 millionEGP · +12.8% vs the same period a year earlier
Operating cash flow-105 millionEGP · −402.0% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q1 2023 was about 9.44 million EGP, down −69.2% from 30.67 million EGP in Q1 2022.
- Total assets at the end of Q1 2023 were about 798 million EGP, and shareholders' equity about 376 million EGP.
- Operating cash flow for Q1 2023 was negative at 105 million EGP.
Key lines against the same period a year earlier
This periodQ1 2022Change
Net profit9.44 million30.67 million−69.2%
Gross profit118 million107 million+11.0%
Total assets798 million641 million+24.5%
Total liabilities421 million307 million+37.2%
Shareholders' equity376 million334 million+12.8%
Total liabilities and equity798 million641 million+24.5%
Operating cash flow-105 million34.73 million−402.0%
Investing cash flow-1.59 million-42.97 thousand−3600.8%
Financing cash flow-51.65 million19.03 million−371.4%
Net change in cash-158 million53.71 million−394.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy